Alnylam Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Alnylam Pharmaceuticals has raised $900M across 1 funding round on record, the most recent a Post-IPO Debt of $900M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alnylam Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Alnylam Pharmaceuticals Funding Rounds
Alnylam Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Alnylam Pharmaceuticals Funding Compared to Other Biotechnology Startups
Alnylam Pharmaceuticals' latest round of $900M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alnylam Pharmaceuticals in Biotechnology and Cambridge
Companies Similar to Alnylam Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Alnylam Pharmaceuticals Funding FAQs
What does Alnylam Pharmaceuticals do?
Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
How much funding has Alnylam Pharmaceuticals raised?
Alnylam Pharmaceuticals has raised $900M across 1 round on record. The most recent is a Post-IPO Debt of $900M announced in Sep 2022.
When did Alnylam Pharmaceuticals last raise funding?
Alnylam Pharmaceuticals' most recent funding round on record is a Post-IPO Debt of $900M, announced in Sep 2022.
Who founded Alnylam Pharmaceuticals?
FundedIQ lists David Bartel (Founder) at Alnylam Pharmaceuticals.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is based in Cambridge, Massachusetts, United States.
How many employees does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals is in the 1001-5000 employee band.
How does Alnylam Pharmaceuticals' funding compare to other Biotechnology startups?
Alnylam Pharmaceuticals' latest round of $900M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Alnylam Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alnylam Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.